Elsevier

Journal of Controlled Release

Volume 148, Issue 1, 20 November 2010, Pages 117-121
Journal of Controlled Release

Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination

https://doi.org/10.1016/j.jconrel.2010.06.009Get rights and content

Abstract

Nasal vaccination is a promising, but challenging vaccination strategy. Poor absorption by the nasal epithelium and failure to break nasal tolerance are regarded as important reasons for poor efficacy of nasally applied vaccines. Formulation of the antigen into mucoadhesive nanoparticles, made of N-trimethyl chitosan (TMC) crosslinked with tripolyphosphate (TPP), has been shown to overcome these obstacles. However, although nasally administered antigen loaded TMC/TPP nanoparticles induce a strong humoral response, antibody subtyping indicates a Th2 bias. To design a nasal antigen delivery system capable of inducing stronger Th1 type responses, TPP as a crosslinking agent was replaced by unmethylated CpG DNA, a TLR-9 ligand and a potent inducer of Th1 responses, to prepare ovalbumin (OVA) loaded TMC nanoparticles (TMC/CpG/OVA). Several physicochemical characteristics of TMC/CpG/OVA (size, zetapotential, loading efficiency and antigen release profile) were assessed and compared to TMC nanoparticles prepared by crosslinking with TPP (TMC/TPP/OVA). Mice were nasally administered TMC/TPP/OVA and TMC/CpG/OVA after which antibody responses in serum and nasal washes were assessed and T-cell activation in the spleens determined.

TMC/CpG/OVA showed similar physical properties as TMC/TPP/OVA in terms of particle size (380 nm), zetapotential (+ 21 mV) and antigen release characteristics. Nasal administration of TMC/CpG/OVA and TMC/TPP/OVA to mice resulted in comparable serum IgG levels (ca. 1000 fold higher than those induced by unadjuvanted OVA) and local secretory IgA levels. Moreover, TMC/CpG/OVA induced a 10 fold higher IgG2a response than TMC/TPP/OVA and enhanced the number of OVA specific IFN-gamma-producing T-cells in the spleen.

In conclusion, OVA loaded TMC nanoparticles, containing CpG as adjuvant and crosslinker, are capable of provoking strong humoral as well as Th1 type cellular immune responses after nasal vaccination.

Introduction

Nasal vaccination has gained much interest over the past decades as it is non-invasive and thereby expected to increase patient compliance. Additionally, vaccination via the nose has been shown to induce, besides systemic humoral (IgG mediated) and cellular responses, local as well as distal secretory immune responses (secretory IgA (sIgA) mediated) [1], [2], [3], making the mucosal linings less vulnerable to infection. Moreover, the cross reactivity of sIgA is relatively high compared to IgG antibodies [4], [5], making the induction of local immune responses a promising strategy to target highly variable pathogens, like influenza viruses [6].

Nonetheless, nasal immunization with subunit vaccines is challenging, as residence time in the nasal cavity is limited and therefore the uptake by the nasal epithelium is low. Moreover, the nasal epithelium is renowned for being a rather tolerogenic site [7], [8], making it difficult for subunit antigens to provoke an immune response. Vaccine formulation may be instrumental to successful nasal vaccination. Encapsulation of the antigen into particulate carrier systems has been explored extensively in recent years [9] and holds great promise as particles can be specifically designed to meet the challenges nasal vaccination provide [10]. Among the large variety of particles that can be found in the literature, chitosan based particles are among the most studied ones [11]. Chitosan is a cheap, biodegradable, mucoadhesive polymer. In rodents, particles prepared from chitosan have been shown to effectively induce systemic antibody responses against ovalbumin (OVA) and cholera toxin [12], Hepatitis B surface antigen [13], and Meningococcal C oligosaccharides [14]. More recently chitosan derivatives have been developed, like thiolated chitosans [15] to enhance its mucoadhesiveness and trimethylated chitosans (TMC) [16] to improve its solubility at physiological pH. Especially TMC has been shown to be a very promising nasal vaccine carrier. Nanoparticles prepared from TMC by ionic crosslinking with tripolyphosphate (TPP) increase the nasal residence time of the encapsulated antigen [17], improve the uptake of the antigen by M-cells [18] and additionally promote maturation of dendritic cells (DCs) [9], [10], [11]. Consequently, TMC particles loaded with antigens, e.g. tetanus toxoid [12], meningococcal C oligosaccharides [19] or hemagglutinin [20] induce strong systemic as well local antibody responses. Moreover, intranasally administered TMC-coated whole inactivated influenza virus resulted in protection of mice against a challenge with a lethal dose of influenza virus [21]. Nonetheless, a significant drawback of TMC is its tendency to promote a humoral (Th2 type) rather than a Th1 type immune response [20], [22]. Strong Th1 type responses are important for many vaccines that we do not have [23], such as HIV/AIDS and tuberculosis vaccines, underscoring the importance of developing vaccine carrier systems capable of inducing these responses. The bias of TMC's adjuvant effect toward a Th2 response is not restricted to the nasal administration route, as it is also observed after intradermal [24] and intramuscular administration of TMC-adjuvanted antigen (unpublished data). However, different types of immune responses have been reported after nasal vaccination [25], [26], [27], [28], depending on the adjuvant used. As TPP does not act as an adjuvant but solely services as a crosslinking agent to promote TMC nanoparticle formation, we propose it should be possible to substitute TPP with a crosslinking agent that does have an adjuvant effect. Unmethylated CpG DNA is a Toll like receptor 9 ligand and described as a Th1 response-inducing adjuvant, also after nasal administration [23]. Furthermore, phosphate groups on CpG render it negatively charged, which could make CpG a possible crosslinking agent to prepare TMC nanoparticles.

The aim of this paper was to study whether CpG can replace TPP as a crosslinker to prepare ovalbumin (OVA)-containing TMC nanoparticles and whether these new carrier systems are capable of redirecting the TMC-induced Th2 type response towards a more Th1 type response, while maintaining strong systemic and local antibody responses. The TMC/CpG/OVA nanoparticles were compared to TMC/TPP/OVA nanoparticles with respect to their physicochemical characteristics and immunogenicity after nasal administration in mice.

Section snippets

Materials

Ovalbumin (OVA) was purchased from Calbiochem (Beeston, UK) and CpG DNA (ODN 2006) as well as fluorescein isothiocyanate coupled CpG (CpG-FITC) from InvivoGen (Toulouse, France). N-trimethyl chitosan with a degree of quaternization of 15% was synthesized from 92% deacetylated (MW 120 kDa) chitosan (Primex, Avaldsnes, Norway) and characterized by NMR, as described by Bal et al. [29]. KCl, NaCl, HNa2PO4, KH2PO4 and bovine serum albumin (BSA) were purchased from Merck (Amsterdam, The Netherlands).

Nanoparticle characterization

The characteristics of the TMC/CpG/OVA nanoparticles and the TMC/TPP/OVA nanoparticles were comparable in size and zetapotential (Table 1). Both particle types showed an average hydrodynamic diameter of ca. 300 nm, were fairly monodisperse (PDI 0.1–0.2) and had a positive zetapotential of about + 20 mV. Moreover, changing the crosslinker did not alter the loading efficiency (Table 1) and the release pattern (data not shown), as both particle showed a burst release followed by no release over 48 h.

Conclusion

TMC/TPP/OVA nanoparticles have previously been shown to be very effective nasal vaccine carriers. Replacing TPP by CpG as a crosslinking agent to obtain TMC/CpG/OVA nanoparticles modulated the immune response towards a Th1 response after nasal vaccination, while maintaining the strong systemic and local antibody responses observed with TMC/TPP nanoparticles. TMC/CpG nanoparticles therefore are an interesting nasal delivery system for vaccines requiring broad humoral as well as strong Th1 type

Acknowledgements

This research was performed under the framework of TI Pharma project number D5-106 “vaccine delivery: alternatives for conventional multiple injection vaccines”. The authors thank Dr. Elly van Riet for reading the manuscript and her valuable suggestions.

References (46)

  • N. Hagenaars et al.

    Relationship between structure and adjuvanticity of N, N, N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine

    J. Control. Release

    (2009)
  • M. Friede et al.

    Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems

    Adv. Drug Deliv. Rev.

    (2005)
  • S.M. Bal et al.

    Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations

    J. Control. Release

    (2010)
  • N. Tanaka et al.

    Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice

    Vaccine

    (2007)
  • J.H. Hamman et al.

    Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia

    Int. J. Pharm.

    (2002)
  • B.I. Florea et al.

    Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation

    J. Control. Release

    (2006)
  • R.J. Verheul et al.

    Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans

    Biomaterials

    (2009)
  • A.F. Kotze et al.

    Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: in vitro evaluation in intestinal epithelial cells (Caco-2)

    J. Pharm. Sci.

    (1999)
  • A. des Rieux et al.

    An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells

    Eur. J. Pharm. Sci.

    (2007)
  • I.M. van der Lubben et al.

    Chitosan for mucosal vaccination

    Adv. Drug Deliv. Rev.

    (2001)
  • D.J. Brayden et al.

    Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting

    Drug Discov. Today

    (2005)
  • S. Fagarasan et al.

    Regulation of IgA synthesis at mucosal surfaces

    Curr. Opin. Immunol.

    (2004)
  • A. Joseph et al.

    Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

    Vaccine

    (2002)
  • Cited by (0)

    View full text